Cardiotonic Agents Market (inotropes) is driven by the management of acute and chronic heart failure, cardiogenic shock, and during cardiac surgery. These drugs increase the force of myocardial contraction. Key drug classes include cardiac glycosides (digoxin), beta-agonists (dobutamine), and phosphodiesterase inhibitors (milrinone).The market is seeing a trend towards the development of novel inotropes with improved safety profiles and fewer arrhythmogenic effects. Key players include Pfizer, Novartis, and Bristol-Myers Squibb. With the high prevalence of heart failure globally and the critical care setting requiring short-term inotropic support, the market remains important, though the focus is shifting towards long-term disease-modifying therapies.
Other Related Reports:www.wiseguyreports.com/reports/antibiotic-disk-dispenser-market
www.wiseguyreports.com/reports/human-cystatin-c-assay-kit-market
www.wiseguyreports.com/reports/preterm-birth-prevention-and-management-market
www.wiseguyreports.com/reports/epilepsy-drug-market
www.wiseguyreports.com/reports/fluvastatin-sodium-drug-market
www.wiseguyreports.com/reports/thymus-cancer-treatment-market
www.wiseguyreports.com/reports/rollator-walker-market
www.wiseguyreports.com/reports/sterile-pre-saturated-wiper-market